HCA Healthcare to offer GRAIL’s Galleri cancer detection test
Md Saiful Islam Khan/iStock via Getty Images

HCA Healthcare (NYSE:HCA), the largest for-profit hospital chain in the U.S., announced a strategic collaboration on Tuesday to provide its patients with the Galleri multi-cancer early detection (MCED) test developed by GRAIL.
Illumina (NASDAQ:ILMN), the current owner of GRAIL, recently received an order from European regulators to divest the unit over its decision to acquire the cancer test developer despite regulatory objections in 2021.

In the U.S., over 60K people die from cancer each year, many due to failure to detect the condition early when it is easier to treat. The prescription-only Galleri test can predict more than 50 cancer types using a single blood sample.
Concurrently, HCA Healthcare (HCA) said it is participating in GRAILâs PATHFINDER 2 study for Galleri in Nashville, Asheville, Austin, and Denver through its Sarah Cannon Research Institute, and its contract research organization.



More on HCA, Illumina, etc.

HCA Healthcare: Rx For Success
HCA Healthcare: Impact Of Medicare Advantage Growth And Demographic Shift
HCA Healthcare Is Beating The Industry
Illumina ordered to divest GRAIL unit in EU
Illumina to quickly divest Grail if it loses EU or US appeal: report